Your browser doesn't support javascript.
loading
Experimental drugs in randomized controlled trials for long-COVID: what's in the pipeline? A systematic and critical review.
Yong, Shin Jie; Halim, Alice; Halim, Michael; Ming, Long Chiau; Goh, Khang Wen; Alfaresi, Mubarak; AlShehail, Bashayer M; Al Fares, Mona A; Alissa, Mohammed; Sulaiman, Tarek; Alsalem, Zainab; Alwashmi, Ameen S S; Khamis, Faryal; Al Kaabi, Nawal A; Albayat, Hawra; Alsheheri, Ahmed; Garout, Mohammed; Alsalman, Jameela; Alfaraj, Amal H; Alhajri, Mashael; Dhama, Kuldeep; Alburaiky, Lamees M; Alsanad, Ahlam H; AlShurbaji, Abdelmunim T; Rabaan, Ali A.
Afiliación
  • Yong SJ; Department of Biological Sciences, School of Medical and Life Sciences, Sunway University, Subang Jaya, Malaysia.
  • Halim A; Shanghai Medical College, Fudan University, Shanghai, China.
  • Halim M; Department of Biomedical Science, School of Science, Engineering and Environment, University of Salford, Greater Manchester, UK.
  • Ming LC; Department of Biological Sciences, School of Medical and Life Sciences, Sunway University, Subang Jaya, Malaysia.
  • Goh KW; Faculty of Data Science and Information Technology, INTI International University, Nilai, Malaysia.
  • Alfaresi M; Department of Pathology and Laboratory Medicine, Zayed Military Hospital, Abu Dhabi, United Arab Emirates.
  • AlShehail BM; Department of Pathology, College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates.
  • Al Fares MA; Pharmacy Practice Department, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
  • Alissa M; Department of Internal Medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
  • Sulaiman T; Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.
  • Alsalem Z; Infectious Diseases Section, Medical Specialties Department, King Fahad Medical City, Riyadh, Saudi Arabia.
  • Alwashmi ASS; Department of Epidemic Diseases Research, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
  • Khamis F; Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia.
  • Al Kaabi NA; Infection Diseases Unit, Department of Internal Medicine, Royal Hospital, Muscat, Oman.
  • Albayat H; College of Medicine and Health Science, Khalifa University, Abu Dhabi, United Arab Emirates.
  • Alsheheri A; Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates.
  • Garout M; Infectious Disease Department, King Saud Medical City, Riyadh, Saudi Arabia.
  • Alsalman J; Infectious Disease Department, King Saud Medical City, Riyadh, Saudi Arabia.
  • Alfaraj AH; Department of Community Medicine and Health Care for Pilgrims, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Alhajri M; Infection Disease Unit, Department of Internal Medicine, Salmaniya Medical Complex, Ministry of Health, Kingdom of Bahrain, Manama, Bahrain.
  • Dhama K; Pediatric Department, Abqaiq General Hospital, First Eastern Health Cluster, Abqaiq, Saudi Arabia.
  • Alburaiky LM; Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
  • Alsanad AH; Division of Pathology, ICAR-Indian Veterinary Research Institute (IVRI), Bareilly, India.
  • AlShurbaji AT; Pediatric Department, Safwa General Hospital, Eastern Health Cluster, Dammam, Saudi Arabia.
  • Rabaan AA; Neonatal Intensive Care Unit, Pediatrics Department, Maternity and Children Hospital, Dammam, Saudi Arabia.
Expert Opin Investig Drugs ; 32(7): 655-667, 2023.
Article en En | MEDLINE | ID: mdl-37534972
INTRODUCTION: Over three years have passed since the emergence of coronavirus disease 2019 (COVID-19), and yet the treatment for long-COVID, a post-COVID-19 syndrome, remains long overdue. Currently, there is no standardized treatment available for long-COVID, primarily due to the lack of funding for post-acute infection syndromes (PAIS). Nevertheless, the past few years have seen a renewed interest in long-COVID research, with billions of dollars allocated for this purpose. As a result, multiple randomized controlled trials (RCTs) have been funded in the quest to find an effective treatment for long-COVID. AREAS COVERED: This systematic review identified and evaluated the potential of current drug treatments for long-COVID, examining both completed and ongoing RCTs. EXPERT OPINION: We identified four completed and 22 ongoing RCTs, investigating 22 unique drugs. However, most drugs were deemed to not have high potential for treating long-COVID, according to three pre-specified domains, a testament to the ordeal of treating long-COVID. Given that long-COVID is highly multifaceted with several proposed subtypes, treatments likely need to be tailored accordingly. Currently, rintatolimod appears to have modest to high potential for treating the myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) subtype, LTY-100 and Treamid for pulmonary fibrosis subtype, and metformin for general long-COVID prevention.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome de Fatiga Crónica / COVID-19 Tipo de estudio: Clinical_trials / Systematic_reviews Límite: Humans Idioma: En Revista: Expert Opin Investig Drugs Asunto de la revista: TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article País de afiliación: Malasia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome de Fatiga Crónica / COVID-19 Tipo de estudio: Clinical_trials / Systematic_reviews Límite: Humans Idioma: En Revista: Expert Opin Investig Drugs Asunto de la revista: TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article País de afiliación: Malasia Pais de publicación: Reino Unido